The CELMoD Initiative: Advancing Community Oncology Readiness in Relapsed/Refractory Multiple Myeloma

Program Description

A majority of patients with multiple myeloma (MM) ultimately relapse, and many progress to triple-class-refractory disease, where survival is poor and IMiD-based regimens often have lesser effectiveness. In this high-risk relapsed/refractory population, next-generation cereblon E3 ligase modulators (CELMoDs) are emerging as oral therapies specifically designed to increase anti-myeloma immune responses while boosting T-cell function. As data for CELMoDs continue to emerge, oncology pharmacists must recognize their potential role to expand oral therapy options in patients with heavily pretreated MM. This session will explore how evolving evidence for dosing and guideline placement for CELMoD-based combinations may impact treatment and management of RRMM. Case discussions will connect pharmacologic properties of CELMoDs, efficacy data, and adverse effect management to real-world decisions about treatment selection, monitoring, and counseling for patients with relapsed/refractory MM in the community setting.

Target audience: Oncology pharmacists

Type of activity: Application

Release date: April 15, 2026

Expiration date: April 16, 2027

Learner level: Advanced

Time to complete activity: 1.0 hour

Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Differentiate cereblon E3 ligase modulators (CELMoDs) from immunomodulatory drugs (IMiDs) and other targeted agents in relapsed/refractory multiple myeloma (RRMM) based on their mechanisms of action, resistance pathways, and pharmacologic properties to support evidence-based clinical decision-making
• Explore pharmacist-led strategies to anticipate, monitor, and manage hematologic toxicities associated with CELMoD-based regimens, including evidence-based interventions for neutropenia prevention and dose optimization in community oncology practice
• Apply emerging clinical evidence to determine where CELMoDs fit within the RRMM treatment continuum, including sequencing with T-cell-directed and other novel therapies, and address practical considerations for integration into community-based care

Accreditation

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-26-063-H01-P. The activity is available for CE credit through April 16, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Sara Scott, PharmD, BCOP, has the following relevant financial relationships with ineligible companies to disclose:

Consultant: Pfizer

Brooke Peters, PharmD, BCOP, has the following relevant financial relationships with ineligible companies to disclose:

Consultant: Amgen, Genentech, Regeneron

Speakers Bureau: Amgen, Janssen, Pfizer, Regeneron

Danai Dima, MD, has the following relevant financial relationships with ineligible companies to disclose:

Consultant: Caribou Biosciences, Kite Pharma, Karyopharm, Pfizer

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Daphne Davis, PharmD, BCOP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:

ceinfo@pharmacytimes.com 

Privacy Policy and Terms of Use Information:

www.pharmacytimes.org/terms